Some Recent Pradaxa Lawsuit Awards

In recent years, worry over the health risks of Pradaxa, a popular blood thinner, has led many people to sue Boehringer Ingelheim, the maker of the medicine. The main complaint against this pharmaceutical company is that it did not warn consumers about the high risk of serious side effects from taking the medicine. One person died and another is undergoing treatment for life-threatening conditions as a result of taking Pradaxa. Such high levels of risk should have been declared to the company by the Food and Drug Administration, but the FDA says it cannot find evidence of such warnings.

Pradaxa Lawsuit

In response to the rising number of lawsuits, and the threat of further litigation, the manufacturer has introduced a safety program to be applied to all of its Pradaxa doses. That program is referred to as the “Risk Management Program for the Risk of Medication interactions with anticoagulant drugs.” The FDA found that the manufacturer’s safety plan was inadequate in preventing or controlling interactions of the two drugs. For example, one consumer is suing because her son became severely ill after consuming Pradaxa, the blood thinner. The case has been settled with the assistance of a legal team working on behalf of the family.

Other plaintiffs’ lawsuits have been awarded on similar grounds, with some settling out of court.

Some of these situations are ongoing, and others have been resolved satisfactorily. A case currently before the United States patent office involves a woman who died from Pradaxa, and her son who is suffering from serious bleeding caused by that medication. The family is appealing a decision that will award them with financial damages.

The company has also introduced a medical device liability lawsuit fund.

The manufacturer has settled such cases in the past through a special fund set up by Congress called the Medical Device Liability Settlement Fund. This fund awards settlements to people whose lives have been destroyed because another person was careless enough to design or manufacture of a defective drug. Such devices may include a blood thinner, insulin pumps, stents used for defibrillators, and pacemakers. When Pradaxa was recalled, this fund was in place to assist manufacturers in paying their rightful obligations to victims of such defective products.

The FDA found that the company’s policies regarding blood thinners indicate that a lower risk is seen with the use of this medication for the short term.

However, it is also clear that this was a mistake, because it was found that a significant number of patients who received Pradaxa actually experienced severe bleeding and an increased risk of stroke. The FDA is now requiring that blood thinners sold under these terms must carry a black box warning. It is not clear yet what the exact definition of a black box warning is. But lawsuits involving this issue will probably continue.

Pradaxa’s policy regarding higher risk of death caused by secondary effects is still unclear.

Some of the lawsuits have been brought against Janssen Pharmaceuticals, the primary supplier of Pradaxa. In one case, a man bled to death on the operating table after taking Pradaxa. These lawsuits could be difficult to win given the fact that the primary manufacturer knows that its drugs cause secondary effects, but is fighting in court to avoid providing any details.

Leave a Reply

Your email address will not be published. Required fields are marked *